Details

Autor(en) / Beteiligte

• Tartaglia, Lawrence J
• Chang, Hui-Wen
• Lee, Benjamin C
• Abbink, Peter
• Ng'ang'a, David
• Boyd, Michael
• Lavine, Christy L
• Lim, So-Yon
• Sanisetty, Srisowmya
• Whitney, James B
• Seaman, Michael S
• Rolland, Morgane
• Tovanabutra, Sodsai
• Ananworanich, Jintanat
• Robb, Merlin L
• Kim, Jerome H
• Michael, Nelson L
• Barouch, Dan H
• Silvestri, Guido

Titel

Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences

Ist Teil von

• PLoS pathogens, 2016-02, Vol.12 (2), p.e1005431-e1005431

Ort / Verlag

United States: Public Library of Science

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Simian-human immunodeficiency virus (SHIV) challenge stocks are critical for preclinical testing of vaccines, antibodies, and other interventions aimed to prevent HIV-1. A major unmet need for the field has been the lack of a SHIV challenge stock expressing circulating recombinant form 01_AE (CRF01_AE) env sequences. We therefore sought to develop mucosally transmissible SHIV challenge stocks containing HIV-1 CRF01_AE env derived from acutely HIV-1 infected individuals from Thailand. SHIV-AE6, SHIV-AE6RM, and SHIV-AE16 contained env sequences that were >99% identical to the original HIV-1 isolate and did not require in vivo passaging. These viruses exhibited CCR5 tropism and displayed a tier 2 neutralization phenotype. These challenge stocks efficiently infected rhesus monkeys by the intrarectal route, replicated to high levels during acute infection, and established chronic viremia in a subset of animals. SHIV-AE16 was titrated for use in single, high dose as well as repetitive, low dose intrarectal challenge studies. These SHIV challenge stocks should facilitate the preclinical evaluation of vaccines, monoclonal antibodies, and other interventions targeted at preventing HIV-1 CRF01_AE infection.